Current stock page

Stock Analysis

Tyra Biosciences, Inc. (TYRA) Stock Analysis

Tyra Biosciences, Inc. (TYRA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TYRA Stock Analysis Summary

Tyra Biosciences, Inc. (TYRA) currently has an AIQ Score of 49/100, indicating a bearish setup. Quality is the strongest factor at 75/100. Momentum is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TYRA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$20.03
AIQ Score49/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$1.38B
P/E Ratio (TTM)-7.59
Forward P/E—
EPS (Q3 FY2026)-$0.74
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta0.53
Volume375.09K
52-week range$14.67-$40.65
RSI 1442.76
50-Day SMA$21.75
200-Day SMA$29.41
Analyst Price Target$43.75
Next EarningsMar 1, 2027
As of Nov 13, 2026 · Market close

TYRATyra Biosciences, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$20.03+$0.26 (+1.32%)

Latest quote

  • Momentum
    27
  • Value
    —
  • Quality
    75
  • Risk resilience
    45
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TYRA Stock Analysis Summary

Tyra Biosciences, Inc. (TYRA) currently has an AIQ Score of 49/100, indicating a bearish setup. Quality is the strongest factor at 75/100. Momentum is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, TYRA has AIQ Score of 49/100 with Quality base of 75/100 and fading Momentum at 27/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (75/100) leads while Momentum (27/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.32% stock move · TYRA classified in Biotechnology.

Current Evidence

BearishTYRA is in a bearish AIQ regime; Quality is the strongest visible factor at 75/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TYRA Bullish or Bearish Right Now?

TYRA currently has a bearish overall setup. Quality is the strongest factor at 75/100, while Momentum is weakest at 27/100. The current evidence suggests a bearish setup.

Bull Case
  • - Quality is supportive at 75/100.
  • - Analyst target implies +118.48% upside from the latest quote.
Bear Case
  • - Momentum is weak at 27/100.
  • - Risk Resilience is weak at 45/100.
  • - Price is -31.91% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (34 vs 6).

Current Consensus

TYRA's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 6 neutral, and 34 sell votes. TYRA's 14-day RSI is 42.76, which places the stock in a weaker momentum range. TYRA's beta is 0.53, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in TYRA?

The largest recent change in TYRA is Quality moving up by 11.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+4.0
Momentum
-1.0
Quality
+11.0
Risk
+0.0

What Would Change the TYRA Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TYRA Decision Framework

Public evidence layers, setup checks, and risk context for Tyra Biosciences, Inc..

Tyra Biosciences, Inc. (TYRA) Stock Analysis

Tyra Biosciences, Inc. has an AIQ Score of 49/100 in a Bearish regime. Quality is strongest at 75/100. Beta is 0.53, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTYRA is in a Bearish AIQ regime with score 49/100.
Signal ConflictThe primary conflict is that quality leads at 75/100 while momentum lags at 27/100.
Factor EvidenceMomentum 27/100 · Quality 75/100 · Risk 45/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 75/100.

TimingFail

Momentum is 27/100 and RSI (14) is 42.8.

Regime fitFail

TYRA is in a Bearish regime at 49/100.

Risk controlFail

Risk factor is 45/100 with beta 0.53 and annual volatility 67.91%.

ConflictWait

Current conflict: quality leads at 75/100 while momentum lags at 27/100.

AIQ Score
49/100
Price
$20.03
Beta
0.53
RSI (14)
42.8

TYRA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TYRA Fundamentals

TYRA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$51.12M
Free cash flow
-$32.3M
View full TYRA fundamental analysis

TYRA Technical Analysis

TYRA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
42.76
Price vs SMA-50
-7.93%
View full TYRA technical analysis

TYRA Stock Catalysts

Track TYRA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 1, 2027
Analyst target
$43.75
News items
5
View TYRA earnings and stock catalysts

TYRA Dividend Analysis

TYRA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TYRA dividend history and analysis

TYRA Financial Data

TYRA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.74
Periods
8
View TYRA financials

TYRA Risk Analysis

TYRA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.53
Risk score
45/100
1Y volatility
67.91%
View TYRA risk analysis

TYRA Stock News

TYRA stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read TYRA stock news

TYRA vs Biotechnology Peers

Current peer cohort: TYRA · URGN · UTHR · VCEL · VKTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TYRA
Current stock
49/100—27/10045/1000.6567.91%Current
URGN
UroGen Pharma Ltd.
53/10064/10040/10040/1000.3961.94%TYRA vs URGN
UTHR
United Therapeutics Corporation
76/10078/10068/10083/1000.7635.02%TYRA vs UTHR
VCEL
Vericel Corporation
77/10065/10090/10064/1000.9345.04%TYRA vs VCEL
VKTX
Viking Therapeutics, Inc.
41/100—47/10041/100-0.1569.18%TYRA vs VKTX
Pairwise Compare links: URGN · UTHR · VCEL · VKTXTYRA vs URGNTYRA vs UTHRTYRA vs VCELTYRA vs VKTXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TYRA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TYRA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.59
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.01
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$51.12M
Quarter free cash flow
-$32.3M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
42.76
MACD
-0.23

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
45/100
Beta
0.53
Annual volatility
67.91%
Max drawdown
-53.24%

TYRA Stock FAQ

What is TYRA stock price today?

Tyra Biosciences, Inc.'s current stock price is $20.03. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TYRA bullish or bearish right now?

TYRA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TYRA's market cap?

TYRA's market cap is $1.38B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TYRA's current P/E ratio?

TYRA's current P/E ratio is -7.59 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TYRA's RSI?

TYRA's 14-day RSI is 42.76 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TYRA above its 50-day and 200-day moving averages?

TYRA is -7.93% from its 50-day SMA and -31.91% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TYRA's next earnings date?

TYRA's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TYRA pay a dividend?

TYRA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.